Inactive Instrument

Highlights Neuralstem, Inc. Nyse

Equities

US64127R3021

End-of-day quote Nyse Other stock markets
- ^USD	-

10/05	Palisade Bio, Inc. announced that it has received $3.999943 million in funding	CI
07/05	Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Palisade Bio?s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide	01/05	CI
Palisade Bio, Inc. Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	23/04	CI
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	16/04	MT
Palisade Bio Shows Bioactivation of PALI-2108 in Study; Shares Rise	16/04	MT
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients? Stool	16/04	CI
Reverse Split: 1 of 15	08/04	FA
North American Morning Briefing : Stocks Seen -2-	02/04	DJ
Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Palisade Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Palisade Bio, Inc. Announces the Appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer	11/23/11	CI
Palisade Bio, Inc. Appoints Mitchell Jones as Chief Medical Officer	11/23/11	CI
Palisade Bio, Inc. Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease	06/23/06	CI
Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Palisade Bio, Inc. Announces Topline Results from U.S. Phase 2 Profile Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions	09/23/09	CI
Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Palisade Bio, Inc. Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study	11/23/11	CI
Palisade Bio, Inc. Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148	05/23/05	CI
North American Morning Briefing : Traders Await -3-	31/23/31	DJ
Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating Lb1148 for Post-Surgical Abdominal Adhesions	16/22/16	CI
Palisade Bio Secures US FDA's Fast Track Designation for Investigational Drug LB1148	22/22/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Neuralstem, Inc. Nyse

Equities

US64127R3021

Highlights

Filters